Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Identifying Changes in Peripheral Lymphocyte Subpopulations in Adult Onset Type 1 Diabetes

  • Teniente Serra, Aina|||0000-0003-3440-804X
  • Pizarro, Eduarda
  • Quirant, Bibiana|||0000-0002-3875-8074
  • Fernández, Marco A.|||0000-0002-3921-2209
  • Vives Pi, Marta|||0000-0003-3735-0779
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
T- and B-lymphocytes play an important role in the pathogenesis of type 1 diabetes (T1D), a chronic disease caused by the autoimmune destruction of the insulin-producing cells in the pancreatic islets. Flow cytometry allows their characterization in peripheral blood, letting to investigate changes in cellular subpopulations that can provide insights in T1D pathophysiology. With this purpose, CD4 + and CD8 + T cells (including naïve, central memory, effector memory and terminally differentiated effector (TEMRA), Th17 and Tregs) and B cells subsets (naïve, unswitched memory, switched memory and transitional B cells) were analysed in peripheral blood of adult T1D patients at disease onset and after ≥2 years using multiparametric flow cytometry. Here we report changes in the percentage of early and late effector memory CD4 + and CD8 + T cells as well as of naïve subsets, regulatory T cells and transitional B cells in peripheral blood of adult patients at onset of T1D when compared with HD. After 2 years follow-up these changes were maintained. Also, we found a decrease in percentage of Th17 and numbers of T cells with baseline. In order to identify potential biomarkers of disease, ROC curves were performed being late EM CD4 T cell subset the most promising candidate. In conclusion, the observed changes in the percentage and/or absolute number of lymphocyte subpopulations of adult T1D patients support the hypothesis that effector cells migrate to the pancreas and this autoimmune process perseveres along the disease. Moreover, multiparametric flow allows to identify those subsets with potential to be considered biomarkers of disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MAP7 and MUCL1 are biomarkers of Vitamin D3-induced tolerogenic dendritic cells in multiple sclerosis patients

  • Navarro-Barriuso, Juan|||0000-0003-2884-4961
  • Mansilla Lopez, Maria Jose|||0000-0002-5044-6313
  • Quirant, Bibiana|||0000-0002-3875-8074
  • Ardiaca-Martínez, Alicia
  • Teniente Serra, Aina|||0000-0003-3440-804X
  • Presas Rodríguez, Sílvia|||0000-0001-8545-2476
  • Ten Brinke, Anja
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
The administration of autologous tolerogenic dendritic cells (tolDC) has become a promising alternative for the treatment of autoimmune diseases, such as multiple sclerosis (MS). Specifically, the use of vitamin D3 for the generation of tolDC (vitD3-tolDC) constitutes one of the most widely studied approaches, as it has evidenced significant immune regulatory properties, both in vitro and in vivo. In this article, we generated human vitD3-tolDC from monocytes from healthy donors and MS patients, characterized in both cases by a semi-mature phenotype, secretion of IL-10 and inhibition of allogeneic lymphocyte proliferation. Additionally, we studied their transcriptomic profile and selected a number of differentially expressed genes compared to control mature and immature dendritic cells for their analysis. Among them, qPCR results validated CYP24A1, MAP7 and MUCL1 genes as biomarkers of vitD3-tolDC in both healthy donors and MS patients. Furthermore, we constructed a network of protein interactions based on the literature, which manifested that MAP7 and MUCL1 genes are both closely connected between them and involved in immune-related functions. In conclusion, this study evidences that MAP7 and MUCL1 constitute robust and potentially functional biomarkers of the generation of vitD3-tolDC, opening the window for their use as quality controls in clinical trials for MS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Optimal response to dimethyl fumarate is mediated by a reduction of Th1-like Th17 cells after 3 months of treatment

  • Mansilla Lopez, Maria Jose|||0000-0002-5044-6313
  • Navarro-Barriuso, Juan|||0000-0003-2884-4961
  • Presas Rodríguez, Sílvia|||0000-0001-8545-2476
  • Teniente Serra, Aina|||0000-0003-3440-804X
  • Quirant, Bibiana|||0000-0002-3875-8074
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
Dimethyl fumarate (DMF) is one of the most promising therapies for relapsing-remitting multiple sclerosis (RRMS) patients since it has shown immunomodulatory and neuroprotective effects. However, a percentage of RRMS patients do not exhibit an optimal response to DMF. The objective of this study was to identify early biomarkers of treatment response by analyzing changes in peripheral leukocyte subpopulations directly in whole blood samples. A longitudinal and prospective study analyzing peripheral blood leukocyte subpopulations in 22 RRMS patients before initiating DMF treatment (baseline) and at 1, 3, 6, and 12 months of follow-up was performed. Differences between no evidence of disease activity (NEDA) and ongoing disease activity (ODA) patients were analyzed. The beneficial effect of DMF was associated with a specific depletion of memory CD4 + and CD8 + T lymphocytes and B cells. Importantly, only NEDA patients showed (a) a shift from a pro- to an antiinflammatory profile, with an increase of Th2 cells and a decrease of Th1-like Th17 lymphocytes; and (b) an increase of regulatory CD56 bright NK cells. The optimal response to DMF is mediated by a shift to antiinflammatory and immunoregulatory profile, which puts forward Th1-like Th17 lymphocytes as a potential early biomarker of treatment response.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Candidate Biomarkers for the Prediction and Monitoring of Partial Remission in Pediatric Type 1 Diabetes

  • Gómez Muñoz, Laia|||0000-0001-9640-6213
  • Perna-Barrull, David|||0000-0003-2079-818X
  • Caroz-Armayones, Josep M.
  • Murillo-Vallés, Marta|||0000-0002-3208-2982
  • Rodríguez-Fernández, Silvia|||0000-0001-8429-4293
  • Valls, Aina|||0000-0002-0751-5029
  • Vázquez, Federico|||0000-0001-6493-2374
  • Pérez Sánchez, Jacobo|||0000-0003-0574-3594
  • Corripio, Raquel|||0000-0003-3344-8269
  • Castaño, Luis|||0000-0003-0437-9401
  • Bel, Joan|||0000-0002-3577-6322
  • Vives Pi, Marta|||0000-0003-3735-0779
The partial remission (PR) phase, a period experienced by most patients with type 1 diabetes (T1D) soon after diagnosis, is characterized by low insulin requirements and improved glycemic control. Given the great potential of this phase as a therapeutic window for immunotherapies because of its association with immunoregulatory mechanisms and β-cell protection, our objective was to find peripheral immunological biomarkers for its better characterization, monitoring, and prediction. The longitudinal follow-up of 17 pediatric patients with new-onset T1D over one year revealed that, during the PR phase, remitter patients show increased percentages of effector memory (EM) T lymphocytes, terminally differentiated EM T lymphocytes, and neutrophils in comparison to non-remitter patients. On the contrary, remitter patients showed lower percentages of naïve T lymphocytes, regulatory T cells (T), and dendritic cells (DCs). After a year of follow-up, these patients also presented increased levels of regulatory B cells and transitional T1 B lymphocytes. On the other hand, although none of the analyzed cytokines (IL-2, IL-6, TGF-β1, IL-17A, and IL-10) could distinguish or predict remission, IL-17A was increased at T1D diagnosis in comparison to control subjects, and remitter patients tended to maintain lower levels of this cytokine than non-remitters. Therefore, these potential monitoring immunological biomarkers of PR support that this stage is governed by both metabolic and immunological factors and suggest immunoregulatory attempts during this phase. Furthermore, since the percentage of T, monocytes, and DCs, and the total daily insulin dose at diagnosis were found to be predictors of the PR phase, we next created an index-based predictive model comprising those immune cell percentages that could potentially predict remission at T1D onset. Although our preliminary study needs further validation, these candidate biomarkers could be useful for the immunological characterization of the PR phase, the stratification of patients with better disease prognosis, and a more personalized therapeutic management.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Corrigendum, Candidate biomarkers for the prediction and monitoring of partial remission in pediatric type 1 diabetes(Front. Immunol., (2022), 13, (825426), 10.3389/fimmu.2022.825426)

  • Gómez Muñoz, Laia|||0000-0001-9640-6213
  • Perna-Barrull, David|||0000-0003-2079-818X
  • Caroz-Armayones, Josep M.
  • Murillo-Vallés, Marta|||0000-0002-3208-2982
  • Rodríguez-Fernández, Silvia|||0000-0001-8429-4293
  • Valls, Aina|||0000-0002-0751-5029
  • Vázquez, Federico|||0000-0001-6493-2374
  • Pérez Sánchez, Jacobo|||0000-0003-0574-3594
  • Corripio, Raquel|||0000-0003-3344-8269
  • Castaño, Luis|||0000-0003-0437-9401
  • Bel, Joan|||0000-0002-3577-6322
  • Vives Pi, Marta|||0000-0003-3735-0779
In the published article, there was an error in the Funding statement. One of the funding bodies was incorrectly listed as "the Spanish Government (FIS PI18/00436)". The correct Funding statement appears below.